Full Press Release Details
| Dr. Reddy s Laboratories Ltd. | ||||
| 8-2-337, Road No. 3, Banjara Hills, | ||||
| Hyderabad - 500 034, Telangana, India. | ||||
| CIN : L85195TG1984PLC004507 | ||||
| Tel :+91 40 4900 2900 | ||||
| Fax :+91 40 4900 2999 | ||||
| Email : mail@drreddys.com www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. | |
| BSE Limited | Exchange Plaza | |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | |
| Mumbai 400 001 | Mumbai 400 051 | |
| Fax Nos.: 022-22723121 / 22723719 / 22722037 / 22722039 | Fax Nos.: 022-26598120/ 26598237/ 26598238 | |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
reference to our intimation dated February 21, 2017 with regard to the audit of our API manufacturing plant at Miryalaguda, by the US FDA, wherein we were issued a form 483 with three observations.
In this regard, we would now like to inform you that we have received an Establishment Inspection Report (EIR) from the US FDA today as closure of audit, for
the above-referred facility.
This is for your information and record.
CC:- New York Stock Exchange Inc. (Stock